Boehringer Ingelheim GmbH has been touting a pipeline which has been being backed by a €3.7bn R&D spend in 2020, 7% up on the previous year and the highest investment in the 136-year history of the German family-owned company.
The R&D spend for BI's human pharma business amounted to €3.28bn, almost 23% of net sales. Speaking at the firm's...








